Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

被引：10

作者：

Costa, Luciano J.

Mailankody, Sham

Shaughnessy, Paul

Hari, Parameswaran

Kaufman, Jonathan L.

Larson, Sarah Marie

Dingli, David

Lee, Kelvin

Conte, Kristin

DeVries, Todd

Piasecki, Julia

Li, Meng

Dubowy, Ronald L.

Htut, Myo

机构：

[1] Univ Alabama Birmingham, Birmingham, AL USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Sarah Cannon Methodist Healthcare Syst, San Antonio, TX USA

[4] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[6] Univ Calif Los Angeles, Los Angeles, CA USA

[7] Mayo Clin, Rochester, MN USA

[8] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[9] Bristol Myers Squibb, Summit, NJ USA

[10] Bristol Myers Squibb, Seattle, WA USA

[11] Bristol Myers Squibb, Princeton, NJ USA

[12] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Myeloma, Arcadia, CA USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.2537

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2537

引用

页数：3